3 ms·
I would think there’s a similar impact on biotech/pharma which relies on research finding candidates to take into development. These companies can burn a whole
by jleyank 1y ago
I would think there’s a similar impact on biotech/pharma which relies on research finding candidates to take into development. These companies can burn a whole lotta money and I think their job market has been brittle over the last year as well. These are ms/phd/md kinds of jobs for the most part. Sudden upturns in laoyff or surrendering companies would confirm the article.
- amacbride 1y agoYes, lots of layoffs in biotech recently (Recursion is a big recent one, although some of that is post-merger restructuring after the Ex Scientia acquisition.)
- mrosett 1y agoThis isn’t really an issue in biotech since companies don’t have any revenue until late in their lives. Ie if I’m doing discovery work for a drug candidate today, it won’t generate revenue for 7+ years. So when if I have to amortize those costs over 5 years, that process will be complete by the time the project generates revenue. I can’t speak to the pharma side as much, but since the 174 issue is most painful for companies with liquidity issues, I doubt it has a huge impact on them.